Conversely, mutant p53 expression trended to reverse the overall survival benefit provided to breast cancer patients whose tumors retain high expression of c-Abl (Supplementary Figure S6), a finding that is highly significant in light of the fact that mutant p53 can promote oncogenic TGF-β signaling [57]. The gene discussed is ABL1; the disease is breast carcinoma.